BioSpace News Archive

The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on November 30, 2022.

SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has named Mr. Donghoon Lee, Executive Vice President and Head of Bio Investment Center of SK Inc., as the new Chief Executive Officer and President of SK Biopharmaceuticals and its U.S. subsidiary SK Life Science.

Liminatus Pharma LLC and Iris Acquisition Corp announced they have entered into a definitive business combination agreement.

Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a price to the public of $12.00 per share.

IVERIC bio, Inc., announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions.